IU Indianapolis ScholarWorks :: Browsing by Subject "Ts65Dn"

Browsing by Subject "Ts65Dn"

Now showing 1 - 6 of 6

Dyrk1a Dynamics: The Influence of Gene Copy Number on Neurodevelopment in the Ts65dn Mouse Model of Down Syndrome
(2024-05) Hawley, Laura E.; Roper, Randall; Belecky-Adams, Teri; Cummins, Theodore; Goodlett, Charles; Hardy, Tabitha; Marrs, Kathleen
Down syndrome (DS) arises from the triplication of human chromosome 21 (Hsa21), leading to a spectrum of phenotypes characterized by neurodevelopmental and cognitive abnormalities. The Ts65Dn mouse model emulates DS by harboring three copies of genes found on Hsa21 resulting in trisomy 21 (Ts21)- like traits, including disruptions in neuronal pathways, delays in sensorimotor and behavior milestones, and deficits in learning and memory tasks. There is no cure for DS and available therapies primarily address symptoms stemming from Ts21-associated phenotypes. DYRK1A, a gene triplicated in Ts21, has a pivotal role in pathways of neurodevelopment and has been a focus of inhibition treatment research aimed at preempting abnormal brain phenotypes. This study aimed to find a point of substantial Dyrk1a expression dysregulation during a period of critical neonatal neurodevelopment and employ targeted pharmacological and genetic knockdown methods to alleviate the presence or severity of characteristically abnormal brain and behavior phenotypes. The hypothesis of this study was that administering a targeted intervention prior to a point of known overexpression in trisomic pups would ameliorate molecular, sensorimotor, and neurobehavioral deficits, redirecting growth trajectories of Ts65Dn neonatal pups towards more neurotypical outcomes. To test this hypothesis, the spatiotemporal pattern of DYRK1A expression was quantified during the first three weeks of neonatal development across the hippocampus, cerebral cortex, and cerebellum of the Ts65Dn mouse model and found to fluctuate according to the genotype, age, sex, and brain region of the subject. Dyrk1a protein and mRNA expression levels were delineated in trisomic animals by age, exploring the correlation between expression and age, sex, genotype, and brain region. Next a constitutive Dyrk1a knockdown model was integrated with the Ts65Dn model to investigate the impact of gene copy number reduction on protein and mRNA expression levels during phases of known DYRK1A dysregulation. On postnatal day 6, protein expression was rescued in all three brain regions of male animals but was rescued only in the cerebellum of females. There were no significant differences in mRNA transcript levels in either sex at this age. Finally, genetic elements were introduced into the Ts65Dn model to facilitate a spatiotemporally controlled functional reduction of Dyrk1a and discern how the timing of gene copy number reduction affects molecular and neurobehavioral development in a trisomic system. Results from these studies suggest that only functionally reducing Dyrk1a gene copy number on the day of birth is not sufficient to rescue the majority of deficits and delays present in the Ts65Dn mouse model of DS. These findings significantly enhance the understanding of trisomic Dyrk1a expression dynamics during neonatal development and shed light on tailored therapeutic approaches to modulate intrinsic DS characteristics based on age, sex, and phenotypic considerations.
Early Chronic Fluoxetine Treatment of Ts65Dn Mice Rescues Synaptic Vesicular Deficits and Prevents Aberrant Proteomic Alterations
(MDPI, 2024-04-03) Fatemi, S. Hossein; Otte, Elysabeth D.; Folsom, Timothy D.; Eschenlauer, Arthur C.; Roper, Randall J.; Aman, Justin W.; Thuras, Paul D.; Biology, School of Science
Down syndrome (DS) is the most common form of inherited intellectual disability caused by trisomy of chromosome 21, presenting with intellectual impairment, craniofacial abnormalities, cardiac defects, and gastrointestinal disorders. The Ts65Dn mouse model replicates many abnormalities of DS. We hypothesized that investigation of the cerebral cortex of fluoxetine-treated trisomic mice may provide proteomic signatures that identify therapeutic targets for DS. Subcellular fractionation of synaptosomes from cerebral cortices of age- and brain-area-matched samples from fluoxetine-treated vs. water-treated trisomic and euploid male mice were subjected to HPLC-tandem mass spectrometry. Analysis of the data revealed enrichment of trisomic risk genes that participate in regulation of synaptic vesicular traffic, pre-synaptic and post-synaptic development, and mitochondrial energy pathways during early brain development. Proteomic analysis of trisomic synaptic fractions revealed significant downregulation of proteins involved in synaptic vesicular traffic, including vesicular endocytosis (CLTA, CLTB, CLTC), synaptic assembly and maturation (EXOC1, EXOC3, EXOC8), anterograde axonal transport (EXOC1), neurotransmitter transport to PSD (SACM1L), endosomal-lysosomal acidification (ROGDI, DMXL2), and synaptic signaling (NRXN1, HIP1, ITSN1, YWHAG). Additionally, trisomic proteomes revealed upregulation of several trafficking proteins, involved in vesicular exocytosis (Rab5B), synapse elimination (UBE3A), scission of endocytosis (DBN1), transport of ER in dendritic spines (MYO5A), presynaptic activity-dependent bulk endocytosis (FMR1), and NMDA receptor activity (GRIN2A). Chronic fluoxetine treatment of Ts65Dn mice rescued synaptic vesicular abnormalities and prevented abnormal proteomic changes in adult Ts65Dn mice, pointing to therapeutic targets for potential treatment of DS.
Effect of Epigallocatechin-3-gallate on a pattern separation task and hippocampal neurogenesis in a mouse model of Down syndrome
(2015) Stringer, Megan Elizabeth; Goodlett, Charles R.; Roper, Randall J.; Neal-Beliveau, Bethany S.; Grahame, Nicholas J.
Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results in an array of phenotypes including intellectual disability. Ts65Dn mice, the most extensively studied DS model, have three copies of ~50% of the genes on Hsa21 and display many phenotypes associated with DS, including cognitive deficits. DYRK1A is found in three copies in humans with Trisomy 21 and in Ts65Dn mice, and is involved in a number of critical pathways including CNS development and osteoclastogenesis. Epigallocatechin-3-gallate (EGCG), the main polyphenol in green tea, inhibits Dyrk1a activity. We have shown that a three-week EGCG treatment (~10mg/kg/day) during adolescence normalizes skeletal abnormalities in Ts65Dn mice, yet the same dose did not rescue deficits in the Morris water maze spatial learning task (MWM) or novel object recognition (NOR). Others have reported that An EGCG dose of 2-3 mg per day (90mg/ml) improved hippocampal-dependent task deficits in Ts65Dn mice. The current study investigated deficits in a radial arm maze pattern separation task in Ts65Dn mice. Pattern separation requires differentiation between similar memories acquired during learning episodes; distinguishing between these similar memories is thought to depend on distinctive encoding in the hippocampus. Pattern separation has been linked to functional activity of newly generated granule cells in the dentate gyrus. Recent studies in Ts65Dn mice have reported significant reductions in adult hippocampal neurogenesis, and after EGCG treatment, enhanced hippocampal neurogenesis. Thus, it was hypothesized that Ts65Dn mice would be impaired in the pattern separation task, and that EGCG would alleviate the pattern separation deficits seen in trisomic mice, in association with increased adult hippocampal neurogenesis. At weaning, Ts65Dn mice and euploid littermates were randomly assigned to the water control, or EGCG [0.4 mg/mL], with both treatments yielding average daily intakes of ~50 mg/kg/day. Beginning on postnatal day 75, all mice were trained on a radial arm maze-delayed non-matching-to-place pattern separation task. Euploid mice performed significantly better over training than Ts65Dn mice, including better performance at each of the three separations. EGCG did not significantly alleviate the pattern separation deficits in Ts65Dn mice. After the behavioral testing commenced, animals were given ad libitum food access for five days, received a 100mg/kg injection of BrdU, and were perfused two hours later. Coronal sections through the dorsal hippocampus were processed for BrdU labeling, and cells were manually counted throughout the subgranular zone of the dentate gyrus. The euploid controls had significantly more BrdU labeled cells than Ts65Dn mice, however, EGCG does not appear to increase proliferation of the hippocampal neuroprogenitor cells. This is the first report of deficits in Ts65Dn mice on a pattern separation task. To the extent that pattern separation depends on the functional involvement of newly generated neurons in an adult dentate gyrus, this approach in Ts65Dn mice may help identify more targeted pharmacotherapies for cognitive deficits in individuals with DS.
Examining Postnatal Retinal Thickness and Retinal Ganglion Cell Count in the Ts65Dn Mouse Model of Down Syndrome
(2023-05) Folz, Andrew; Roper, Randall; Goodlett, Charles; Belecky-Adams, Teri
Down syndrome (DS) is a genetic condition caused by the triplication of human chromosome 21 and presents with many phenotypes including decreased brain size, hypocellularity in the brain, and assorted ocular phenotypes. Some of the ocular phenotypes seen are increased risk of cataracts, accommodation difficulties, increased risk of refractive errors, and increased retinal thickness. The Ts65Dn mouse model of DS is a classically used mouse model as it presents a number of phenotypes also seen in those with DS. Some of these phenotypes include decreased brain volume, abnormal synaptic plasticity, and ocular phenotypes. These ocular phenotypes include decreased visual acuity, cataracts, and increased retinal thickness. The Ts65Dn mouse model is trisomic for Dyrk1a, a gene of interest in DS research. We hypothesize that there will be a genotypic and sex effect of retinal thickness and retinal ganglion cell (RGC) count at postnatal day 15 in the Ts65Dn mouse model of DS. Retinal slices were taken from male and female trisomic and euploid Ts65Dn mice at P15 and fluorescently labeled for RGCs and bipolar cells via immunohistochemistry. The retinas were measured for total retinal thickness and RNA-binding protein (RBPMS) positive cells in the RGC layer were counted. There was no genotypic or sex effect when comparing retinal thickness in trisomic mice as compared to euploid mice. There was a genotypic effect of RBPMS positive cell count in which the trisomic mice had a higher number of RBPMS positive cells than euploid mice. Increased retinal thickness along with increased RGC number have both been implicated with decreased apoptosis in the retina. In the Ts65Dn mouse model along with in individuals with DS, this could be due to an increase in DYRK1A protein levels reducing apoptosis. In future studies, determining DYRK1A’s influence in retinal thickness and RGC number could result in a treatment for overactive DYRK1A that could normalize retinal thickness and RGC number in those with DS.
The identification of increased Dyrk1a protein levels in Ts65Dn mice guides the targeted administration of the novel Dyrk1a inhibitor CX-4945
(2018-04-27) Stringer, Megan; Goodlett, Charles; Roper, Randall
Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results in phenotypes including intellectual disability. Ts65Dn mice, the most extensively studied DS model, have three copies of ~50% of the genes on Hsa21 and display many phenotypes associated with DS, including cognitive deficits. DYRK1A is a dosage-sensitive gene found in three copies in humans with Trisomy 21 and in Ts65Dn mice and is involved in CNS development. Overexpression of DYRK1A is hypothesized to cause many of the cognitive and developmental deficits observed in DS and has been touted as a target for drug development in DS. Definitive evidence that excessive expression/activity of Dyrk1a directly contributes to specific phenotypes in DS mouse models is limited, and there is no direct evidence that verified pharmacological inhibition of Dyrk1a in vivo causes enduring improvement in DS cognitive phenotypes. In part, this reflects the remarkably limited knowledge of the temporal regulation of Dyrk1a expression and activity in different brain regions across development in DS mouse models. To establish the therapeutic potential of Dyrk1a inhibitors, the first aim of this study was to determine when and in what brain regions excessive Dyrk1a is evident and to identify developmental periods when elevated expression of Dyrk1a may be contributing to enduring aberrant functional development. This aim provided systematic quantification of Dyrk1a protein level at key postnatal (P) ages (P12, P15, P18, P24 P30, P42) in Ts65Dn mice, at ages of translational relevance to clinical applications in humans (birth, early adolescence, late adolescence, young adult). Western blot analysis showed that significant elevation of Dyrk1a with the largest effect sizes occurred in trisomic mice on P15. The second aim of this study was to test whether treating Ts65Dn with a novel Dyrk1a inhibitor (CX-4945) during the time of Dyrk1a elevation would rescue the behavioral and structural abnormalities observed. From P14-P18, Ts65Dn and euploid mice were treated with 75mg/kg CX-4945 or DMSO (vehicle) and tested on a homing task and locomotor activity in a novel arena on P17-P18, counterbalanced for order. At the cessation of treatment, hippocampal cell proliferation was assessed. While there was a lack of statistically significant improvements with CX-4945 treatment, there were modest effect sizes. In addition, several of the behavioral studies were significantly underpowered, making it difficult to conclusively ascertain the efficacy of CX-4945 on specific phenotypes. Nevertheless, this study demonstrates that Dyrk1a is dynamically expressed across development in mice, and suggests that consideration of the spatial and temporal expression of Dyrk1a may well be critical in the development of therapeutics for DS.
MOLECULAR MECHANISMS ALTERING SKELETAL DEVELOPMENT AND HOMEOSTASIS IN TS65NDN DOWN SYNDROME MICE
(Office of the Vice Chancellor for Research, 2012-04-13) Blazek, Joshua D.; Malik, Ahmed; Roper, Randall J.
Down syndrome (DS) is caused by three copies of human chromosome 21 (HSA21) and results in abnormal craniofacial and appendicular bone phe-notypes. The Ts65Dn mouse model of DS contains three copies of nearly half of the genes found on HSA21, and exhibits craniofacial skeletal phenotypes similar to those observed in humans with DS. We recently demonstrated ab-normalities in the development and homeostasis of the appendicular skele-ton of Ts65Dn mice. Femurs from trisomic mice exhibit alterations in trabec-ular bone architecture and overall bone strength. Furthermore, bone for-mation rates were found to be significantly reduced, suggesting trisomy im-pacts bone development and maintenance in Ts65Dn mice, and by extension humans with DS. DYRK1A is triplicated in both humans with DS and Ts65Dn mice and its protein acts as a kinase critical during development. Dyrk1A negatively regulates the nuclear localization and activation of Nfatc, a tran-scription factor critical to signaling pathways associated with cell proliferation and bone development, and is overexpressed in the E9.5 Ts65Dn mandible precursor. We hypothesize that the previously documented Ts65Dn bone phenotype originates during embryonic development, and the presence of an extra copy of Dyrk1a contributes to the abnormal bone phenotype observed in Ts65Dn mice and humans with DS. To test our first hypothesis, analysis of the cartilage template and early bone precursor is being conducted on the femurs from embryonic day 17.5 trisomic and euploid embryos. To implicate the involvement of Dyrk1a in the DS bone phenotype, Ts65Dn mice are be-ing treated with a known Dyrk1a inhibitor, EGCG, to determine if correcting the functional expression of Dyrk1a impacts the development of the Ts65Dn postnatal bone phenotype. Understanding the molecular mechanisms under-lying DS bone phenotypes may help improve the quality of life for individuals with DS and provide viable options for the treatment of osteoporosis.

Browsing by Subject "Ts65Dn"

Results Per Page

Sort Options